Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
Last trade$17.32
Day change-$1.165 (-6.30%)
Day range$17.25 – $18.77
Volume1,021,861
Market cap$1.29B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.29B
Price / earnings
—
Price / book
9.55×
Price / sales
1.2×
EV / sales
1.69×
EV / EBITDA
-248.71×
Profitability
Earnings per share
-$0.71
Return on assets
-4.25%
Return on equity
-36.45%
Dividend yield
0%
Liquidity and leverage
Debt / equity
4.47×
Current ratio
3.21×
Quick ratio
2.65×
Cash ratio
0.28×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$114.88M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TNDM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$283.69M
$254.56M
$247.22M
$290.38M
$249.25M
$240.68M
$234.42M
$282.65M
Cost of revenue
$123.27M
$109.78M
$110.43M
$122.92M
$114.96M
$114.82M
$116.02M
$125.19M
Gross profit
$160.42M
$144.78M
$136.79M
$167.46M
$134.29M
$125.86M
$118.41M
$157.46M
Selling, general and administrative
$113.95M
$111.64M
$108.19M
$113.1M
$108.44M
$109.6M
$113.85M
$105.84M
Research and development
$48.85M
$46.93M
$46.04M
$46.07M
$48.72M
$48.12M
$50.22M
$52.2M
Total operating expenses
$162.79M
$158.57M
$154.22M
$159.17M
$157.16M
$177.67M
$239.29M
$158.04M
Operating income
-$2.37M
-$13.79M
-$17.43M
$8.29M
-$22.86M
-$51.81M
-$120.88M
-$582K
Interest expense
-$2.31M
-$2.45M
-$2.2M
-$2.08M
-$2.07M
-$1.91M
-$1.86M
-$1.86M
Income before taxes
-$7.69M
-$20.66M
-$19.88M
$4.68M
-$25.14M
-$57.72M
-$122.09M
$16K
Income taxes
-$608K
$510K
$516K
$5.27M
-$3.98M
-$5.32M
$8.47M
-$739K
Net income
-$7.09M
-$21.17M
-$20.39M
-$589K
-$21.17M
-$52.4M
-$130.56M
$755K
Net income attributable to common shareholders
-$7.09M
-$21.17M
-$20.39M
-$589K
-$21.17M
-$52.4M
-$130.56M
$755K
EBITDA
$2.14M
-$9.32M
-$12.93M
$12.79M
-$18.37M
-$27.49M
-$41.35M
$3.66M
Basic earnings per share
-$0.10
-$0.31
-$0.30
-$0.01
-$0.31
-$0.78
-$1.97
$0.01
Diluted earnings per share
-$0.10
-$0.31
-$0.30
-$0.01
-$0.31
-$0.78
-$1.97
$0.01
Recent news
Company coverage with links to the original publishers.
Tandem Diabetes Care reported Q3 2026 revenue of $283.69 million, up 13.8% year-over-year and beating consensus estimates by 6.94%. EPS of -$0.10 significantly outperformed the -$0.27 estimate. International sales grew strongly at 25.8%, while supplies revenue surged 21.3%. However, pump sales in the US declined 1.7%. Despite strong recent stock performance (+20.3% over the past month), the company holds a Zacks Rank #4 (Sell) rating.
Tandem Diabetes Care reported a Q3 loss of $0.1 per share, beating consensus estimates of -$0.27 loss, representing a 62.96% earnings surprise. Revenue reached $283.69 million, surpassing estimates by 6.94% and up from $249.25 million year-ago. However, the stock has underperformed the market by 13.3% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.
Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026.
Tandem Diabetes (TNDM) is positioned for growth with its expanding product roadmap including the Mobi tubeless pump, new CGM integrations, and AIDANET closed-loop program. The company's pay-as-you-go reimbursement model aims to lower upfront barriers and boost recurring supply revenue. However, macroeconomic pressures, reimbursement sensitivity, competitive threats, and the impact of GLP-1 drugs on insulin therapy demand pose significant headwinds to sustained profitability.
The global aging population is reshaping healthcare investment opportunities, with the geriatric care services market projected to grow from $1.24 trillion in 2025 to $2.16 trillion by 2034. Healthcare companies are capitalizing on this demographic shift through innovations in diabetes care, cardiovascular treatments, robotic surgery, and digital health solutions. Key players like AbbVie, Tandem Diabetes Care, Amgen, Stryker, and Boston Scientific are advancing AI-enabled technologies and specialized treatments for age-related conditions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.